Chimerix, Omthera price IPOs
Infectious disease company Chimerix Inc. (NASDAQ:CMRX) and hypertriglyceridemia company Omthera Pharmaceuticals Inc. (NASDAQ:OMTH) both priced IPOs on Thursday. Chimerix priced in the middle of its proposed range and bumped up the number of shares, while Omthera also sold more shares but below its proposed range. Chimerix raised $102 million through the sale of 7.3 million shares at $14, which values the company at $341.7 million. Earlier this month, the company said it planned to sell 6.1 million shares at $13-$15. Morgan Stanley; Cowen; William Blair; and Lazard are underwriters. Chimerix was up $4.79 (34%) to $18.79 in its first day of trading on Thursday.
This year, Chimerix plans to start the Phase III SUPPRESS trial of CMX001 to prevent cytomegalovirus (CMV) infection in high-risk hematopoietic stem cell transplant (HSCT) recipients. Chimerix also is developing the compound under a contract with HHS's Biomedical Advanced Research and Development Authority (BARDA) to prevent smallpox infection. ...